etomoxir has been researched along with Acute Myelogenous Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aller, P; Boyano-Adánez, Mdel C; Calviño, E; Calvo, S; de Blas, E; Estañ, MC; Guillén-Guío, B; Rial, E | 1 |
2 other study(ies) available for etomoxir and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Apoptotic efficacy of etomoxir in human acute myeloid leukemia cells. Cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Deoxyglucose; Epoxy Compounds; Glycolysis; Humans; Indazoles; Leukemia, Myeloid, Acute; Oxidative Stress; Oxides; Protein Kinases | 2014 |
Shedding Light on Fat Dependence in AML.
Topics: Acetyl-CoA Carboxylase; Adenylate Kinase; Epoxy Compounds; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Leukemia, Myeloid, Acute; Lipid Metabolism; Oxidation-Reduction; Phosphorylation; Ranolazine; Tumor Cells, Cultured | 2016 |